Travere Therapeutics (NASDAQ:TVTX – Free Report) had its price target lowered by Piper Sandler from $19.00 to $10.00 in a research note released on Wednesday, Benzinga reports. The firm currently has a neutral rating on the stock. TVTX has been the subject of several other research reports. JPMorgan Chase & Co. started coverage on Travere […]
Travere Therapeutics (NASDAQ:TVTX – Free Report) had its price target trimmed by HC Wainwright from $32.00 to $18.00 in a report published on Friday, MarketBeat reports. The firm currently has a buy rating on the stock. Other equities analysts also recently issued research reports about the stock. Wells Fargo & Company downgraded shares of Travere […]
Travere Therapeutics (NASDAQ:TVTX – Free Report) had its price target decreased by Barclays from $31.00 to $12.00 in a report released on Friday, MarketBeat reports. Barclays currently has an overweight rating on the stock. Other equities research analysts also recently issued reports about the company. HC Wainwright decreased their price target on Travere Therapeutics from […]
Travere Therapeutics (NASDAQ:TVTX – Free Report) had its price target decreased by Bank of America from $41.00 to $27.00 in a research report report published on Friday, Marketbeat Ratings reports. Bank of America currently has a buy rating on the stock. Several other brokerages also recently weighed in on TVTX. JPMorgan Chase & Co. assumed […]
Evercore ISI restated their outperform rating on shares of Travere Therapeutics (NASDAQ:TVTX – Free Report) in a research note published on Tuesday morning, Benzinga reports. The brokerage currently has a $30.00 target price on the stock. TVTX has been the subject of several other reports. Canaccord Genuity Group reduced their target price on Travere Therapeutics […]